Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer — Decera Clinical Education Oncology Podcast

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy.

Key topics include:

Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs
Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA
Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease
Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue
Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy
Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support

Presenters
Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Oncology Clinical Pharmacy Specialist
Allegheny Health Network
Pittsburgh, Pennsylvania

Jordan Hill, PharmD, BCOP
Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program:

Link to full program:
https://bit.ly/4gvZerW

And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios.

Early Breast Cancer:
https://bit.ly/4gtUiUq

AKT or PI3K Inhibitors in MBC:
https://bit.ly/4qcyBvk

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.